📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-19 21:01
144 analysed today
144
Today
136,664
All-time analysed
40,493
Positive
6,319
Negative
81,911
Neutral
7,873
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
43 announcements match the current filters (relevance ≥ 5).
100% Share Pledge Released: API Holdings Repays ₹1,700 Cr NCDs
Thyrocare Technologies announced the complete release and discharge of transaction documents following the full redemption and repayment of ₹1,700 crore Non-Convertible Debentures (NCDs) by ultimate parent API Holdings Limited. The NCDs were previously secured by a pledge on 60.92% of Thyrocare's equity capital held by promoter Docon Technologies. Debenture trustee Catalyst Trusteeship issued a No-Dues and Release Certificate on August 19, 2026, fully clearing the promoter share pledge overhang.
Confidence: HIGH
What changedAPI Holdings fully redeemed its ₹1,700 crore NCDs, leading to the complete revocation of the pledge on Docon Technologies' 60.92% equity stake in Thyrocare.
Why it mattersThe complete removal of promoter share encumbrance eliminates a major structural overhang and potential distress sale risk for Thyrocare shareholders.
Parent NCD Value Repaid: INR 1,700 crorePromoter Stake Unpledged: 60.92%No-Dues Certificate Date: August 19, 2026Company Market Cap: Rs 6156 Cr
📅 Short termPositive sentiment driver as the complete release of pledged shares removes an encumbrance overhang on the stock.
📈 Long termEnhances corporate governance and capital structure clarity for minority shareholders, allowing the market to focus purely on business execution and diagnostic volume growth.
Key Highlights
Full redemption and repayment of INR 1,700 crore NCDs completed by parent API Holdings Limited.
Entire pledged promoter stake of 60.92% in Thyrocare held by Docon Technologies stands fully released.
Debenture trustee Catalyst Trusteeship Limited issued the No-Dues and Release Certificate on August 19, 2026.
Transaction documents executed on September 11, 2025 are completely discharged with zero operational impact on Thyrocare.
👀 What to Watch
Track subsequent shareholding pattern filings to confirm zero pledged promoter shares, and monitor operational performance in upcoming quarterly earnings.
Promoter Releases 100% Pledged Shares (49.93% Equity) After ₹1,050 Cr NCD Repayment
Docon Technologies, the promoter of Thyrocare Technologies, has secured the complete release of pledge over 7,94,69,696 equity shares, representing 49.93% of the company's total equity. This release follows the full redemption and repayment of ₹1,050 crore (INR 10,500 million) worth of Non-Convertible Debentures (NCDs) by its parent company, API Holdings Limited, on August 14, 2026. Following this action, Docon's entire holding of 8,12,00,000 equity shares (51.02% stake) is completely free from encumbrance. The debt clearance was funded via internal accruals and prior sale of 1,57,69,696 shares by the promoter.
Confidence: HIGH
What changedPromoter Docon Technologies fully removed the encumbrance on 7,94,69,696 equity shares (49.93% stake) after parent entity API Holdings repaid ₹1,050 crore in NCDs.
Why it mattersThe complete removal of promoter pledge eliminates lender invocation risk and debt overhang from the parent entity, significantly improving corporate governance perception.
Shares released from pledge: 7,94,69,696Share capital released: 49.93%NCD debt repaid: INR 10,500 millionPost-event promoter holding: 51.02%Encumbered shares post-release: 0
📅 Short termLikely to provide positive sentiment in the trading sessions as the overhang of promoter share encumbrance is entirely removed.
📈 Long termClears holding company debt uncertainty, allowing valuation multiples to reflect underlying operating performance and franchise growth in the diagnostics sector.
Key Highlights
Pledge released on 7,94,69,696 equity shares, representing 49.93% of the total share capital.
Promoter share encumbrance reduced to zero, leaving Docon's entire 51.02% stake unencumbered.
Triggered by API Holdings Limited's full repayment of INR 10,500 million (₹1,050 crore) NCDs on August 14, 2026.
Repayment was funded through internal accruals of API Holdings and prior secondary stake sales of 1,57,69,696 shares.
👀 What to Watch
Track the upcoming quarterly shareholding patterns to verify zero pledge status, and focus on core operating performance and network expansion across diagnostic markets.
9.90% Stake Sale: Promoter Docon Technologies offloads 1.57 Cr shares in Thyrocare
Promoter Docon Technologies Private Limited sold 1,57,69,696 equity shares of Thyrocare Technologies, representing 9.90% of the company's total capital. The sale was conducted via market trades on August 13, 2026, reducing the promoter's stake from 60.92% to 51.02%. While Docon remains the majority shareholder and promoter, this significant divestment increases the public float. Investors should monitor the buyer profile to see if institutional interest has increased to absorb this supply.
Confidence: HIGH
What changedPromoter Docon Technologies reduced its ownership in Thyrocare by 9.90% through open market sales.
Why it mattersThis is a material reduction in promoter skin-in-the-game, although they retain majority control at 51.02%. It significantly increases the stock's free float and may impact short-term price discovery.
Shares sold: 1,57,69,696Stake sold (%): 9.90%Post-sale Promoter Holding: 51.02%Pre-sale Promoter Holding: 60.92%Transaction Date: August 13, 2026
📅 Short termThe stock may face technical pressure or increased volatility in the coming days as the market absorbs the 9.9% increase in tradable supply.
📈 Long termThe promoter retains majority control (51.02%), suggesting no immediate change in strategic direction; long-term value remains tied to the 18-22% growth guidance and diagnostic market penetration.
⚠ Risk flags
- Significant promoter stake reduction
- Potential for further supply if promoter needs liquidity
- Unstated reason for the divestment
Key Highlights
1,57,69,696 shares sold by promoter Docon Technologies via market trades
9.90% reduction in total paid-up equity share capital
Promoter holding decreased from 60.92% to 51.02% following the transaction
Transaction date confirmed as August 13, 2026
👀 What to Watch
Check exchange bulk and block deal data to identify if the 9.9% stake was absorbed by long-term institutional investors or dispersed into the retail market.
1.75 Cr Shares (10.99%) Released from Pledge by Promoter Docon Technologies
Promoter Docon Technologies Private Limited has released a pledge on 1.75 crore equity shares of Thyrocare, representing 10.99% of the company's total share capital. This move reduces the total encumbered promoter holding from 60.92% to 49.93%. The shares were originally pledged as security for Rs 1,050 crore in Non-Convertible Debentures (NCDs) issued by the parent entity, API Holdings Limited. While the total promoter stake remains unchanged at 60.92%, the reduction in pledged shares decreases the risk of forced liquidation.
Confidence: HIGH
What changedThe promoter's encumbered (pledged) shareholding has decreased by 10.99% of the company's total capital following a release by the debenture trustee.
Why it mattersHigh promoter pledge is often viewed as a risk; a reduction indicates improved financial flexibility at the promoter/parent level and reduces the potential for a margin-call-driven sell-off in the market.
Shares released: 1,75,00,000% of total capital released: 10.99%Remaining pledged stake: 49.93%Parent company NCD debt: Rs 1,050 crTotal promoter stake: 60.92%
📅 Short termThe news is likely to be received positively by the market as it reduces the 'overhang' associated with high promoter pledges.
📈 Long termWhile a positive step, nearly 50% of the company's total capital remains pledged. Structural long-term confidence will improve as this figure continues to decline.
⚠ Risk flags
- High remaining promoter pledge (49.93% of total capital)
- Significant parent company debt (Rs 1,050 cr)
Key Highlights
1,75,00,000 equity shares released from pledge on August 11, 2026
Released shares represent 10.99% of the total equity share capital of the company
Total pledged promoter holding reduced from 60.92% to 49.93% post-event
Underlying debt for which shares were pledged is Rs 1,050 crore (INR 10,500 million) in NCDs
Docon Technologies continues to hold a total of 9,69,69,696 shares (60.92% stake)
👀 What to Watch
Investors should monitor the remaining 49.93% pledged stake and the debt-servicing capability of the parent company, API Holdings, as further releases would continue to de-risk the stock.
Thyrocare Q1 FY27: Pathology Revenue Grows 26% YoY; Franchisee Network Reaches 11,700+
Thyrocare reported a robust Q1 FY27 with consolidated revenue increasing 24% YoY, led by a 26% surge in its core pathology business. The company has successfully scaled its active franchisee network to over 11,700 centers, a fourfold increase since the 2021 management change. Management is now pivoting towards high-value 'Specialty Diagnostics' like genomics and allergy testing, targeting a 15-20% revenue share in the medium term. Despite adding 900 franchisees in Q1, the company maintains a conservative full-year net addition target of 1,700 to account for potential churn.
Confidence: HIGH
What changedThe company transitioned from a routine-testing focus to a high-growth, specialty-led diagnostic model with a significantly expanded physical lab and franchisee footprint.
Why it mattersThe 26% pathology growth confirms that Thyrocare is gaining market share under new management, while the shift to specialty tests aims to protect margins in a competitive diagnostic landscape.
Pathology Revenue Growth (YoY): 26%Consolidated Revenue Growth (YoY): 24%Active Franchisees: 11,700New Franchisees Added (Q1): 900Specialty Revenue Target: 15-20%
📅 Short termThe stock may see positive momentum as the 24-26% growth rates exceed the company's own long-term guidance of 18-22%.
📈 Long termThe expansion from 17 to 44 labs and a 4x increase in franchisees creates a structural competitive advantage in logistics and turnaround time for pan-India diagnostic services.
⚠ Risk flags
- Franchisee churn (management noted not all 900 Q1 additions may remain active)
- Intense pricing competition in the diagnostic industry
- Execution risk in the international foray into Africa
Key Highlights
Pathology business revenue grew 26% YoY in Q1 FY27, significantly outperforming the industry's mid-teen growth rates.
Active franchisee network reached 11,700+, adding 900 new partners in the first quarter alone.
Laboratory infrastructure expanded to 44 labs from 17 in FY21, with 100% of labs now NABL affiliated.
Aarogyam preventive health brand grew 21% YoY, while the Jaanch curative brand grew 36% YoY.
Test menu has expanded fivefold to more than 1,375 tests since the acquisition by API Holdings in 2021.
👀 What to Watch
Monitor the revenue contribution from the new 'Specialty Diagnostics' segment and the retention rate of the 900 franchisees added this quarter to gauge long-term scalability.
Thyrocare Q1 FY27 Revenue Grows 24% YoY to ₹240 Cr; Resubmits Results in Machine-Readable Format
Thyrocare Technologies reported a strong start to FY27 with consolidated revenue reaching ₹240.02 Cr, a 24.3% increase from ₹193.03 Cr in Q1 FY26. Profit before tax (PBT) saw a significant jump of 35.3% YoY to ₹68.29 Cr, driven by the core Diagnostic Testing segment which contributed 94% of total revenue. The company maintained healthy margins with standalone EPS rising to ₹3.15 from ₹2.27 YoY. This specific filing is a procedural resubmission in a machine-readable format as requested by the NSE.
Confidence: HIGH
What changedThe company resubmitted its previously announced Q1 FY27 financial results in a machine-readable format following a compliance request from the National Stock Exchange.
Why it mattersThe results confirm that Thyrocare is outperforming the broader diagnostic industry's mid-teen growth rates, demonstrating strong execution in its core pathology business and effective cost management.
Consolidated Revenue (Q1 FY27): ₹240.02 CrRevenue vs TTM Revenue: 29.4%Consolidated PBT: ₹68.29 CrStandalone EPS: ₹3.15Diagnostic Segment Revenue: ₹226.21 Cr
📅 Short termThe stock may react positively to the strong double-digit growth in both revenue and profitability reported for the first quarter.
📈 Long termThe company's focus on high-volume, affordable diagnostics and its expansion into international markets like Tanzania provide a structural growth runway.
⚠ Risk flags
- Competitive pricing pressure in the diagnostic market
- Seasonality (Q3 is typically a soft quarter)
- High dependence on the franchise/B2B network
Key Highlights
Consolidated revenue for Q1 FY27 grew 24.3% YoY to ₹240.02 Cr
Profit before tax (PBT) increased by 35.3% YoY to ₹68.29 Cr from ₹50.48 Cr
Diagnostic Testing Services revenue reached ₹226.21 Cr, up from ₹178.33 Cr in the previous year's quarter
Standalone net profit for the quarter stood at ₹50.17 Cr compared to ₹36.05 Cr YoY
Imaging Services segment contributed ₹13.48 Cr to the total revenue
👀 What to Watch
Investors should monitor the sustainability of the 24% revenue growth rate against the company's long-term target of 18-22% and track the expansion of the franchise network which currently adds 100-150 centers monthly.
Q1 FY27 Earnings Call: Thyrocare Releases Audio Recording of July 23, 2026 Meeting
Thyrocare Technologies has released the audio recording of its earnings conference call for the quarter ended June 30, 2026, held on July 23, 2026. The call provides management's perspective on the company's performance against its 18-22% growth target and its network of 10,100+ active centers. With a TTM revenue of Rs 815 Cr and a high ROCE of 36.0%, the discussion likely covered the progress of the international expansion in Tanzania and the 'ECG at home' service. This is a routine but essential disclosure for understanding the qualitative drivers behind the latest quarterly numbers.
Confidence: HIGH
What changedThe company has made the audio recording of its post-results investor call publicly available on its website.
Why it mattersEarnings calls provide critical context on operational efficiency and procurement-led margin expansion, which are key to Thyrocare's 'affordable player' strategy in a competitive diagnostic market.
Call Date: July 23, 2026Quarter Ended: June 30, 2026TTM Revenue: Rs 815 CrActive Centers: 10,100+Monthly Franchisee Addition: 100-150TTM OPM: 31.9%
📅 Short termNeutral; the market will likely wait for the full transcript to identify specific growth catalysts or margin headwinds discussed during the call.
📈 Long termStructural growth remains tied to the company's ability to maintain high-teen growth rates and successfully scale its international foray in Tanzania.
⚠ Risk flags
- Competitive pricing pressure in the pathology segment
- Seasonality impacts (Q3 typically soft)
Key Highlights
Earnings conference call conducted on July 23, 2026, at 06:00 PM IST.
Recording pertains to the unaudited financial results for the quarter ended June 30, 2026.
Company currently operates a network of over 10,100 active franchise centers.
Management continues to target a monthly addition of 100-150 net franchisees.
TTM Operating Profit Margin (OPM) stands at 31.9% as of the latest reporting cycle.
👀 What to Watch
Investors should review the upcoming transcript to assess management's commentary on volume growth versus pricing pressure and the execution timeline for the African expansion.
Thyrocare Board Approves Evaluation to Restructure or Exit Radiology Business (NHL)
Thyrocare's Board has granted in-principle approval to evaluate the restructuring of its wholly-owned subsidiary, Nueclear Healthcare Limited (NHL), which manages the radiology and nuclear medicine business. The company is considering various modes including a demerger, slump sale, or business transfer to move this unit outside the group. With pathology currently contributing 89% of total business, this move indicates a strategic shift toward becoming a pure-play pathology provider. The restructuring is currently at an early evaluation stage with no final terms disclosed.
Confidence: HIGH
What changedThe company has officially initiated a process to potentially divest or separate its non-core radiology business from its core pathology operations.
Why it mattersRadiology is capital-intensive compared to pathology; exiting this segment could improve Thyrocare's overall margins and return on capital (ROCE currently 36%) by focusing on its 89% pathology core.
Pathology Revenue Contribution: 89%Subsidiary Ownership (NHL): 100%TTM Revenue: Rs 815 CrMarket Cap: Rs 4326 CrBoard Meeting Duration: 50 minutes
📅 Short termThe stock may see speculative interest as the market anticipates the valuation of the radiology business and the potential for a cash payout or value unlocking.
📈 Long termStructurally positive as it simplifies the business model into a pure-play pathology firm, potentially leading to a valuation re-rating if margins improve.
⚠ Risk flags
- Execution risk in the restructuring process
- Valuation uncertainty for the radiology assets
- Regulatory and tax hurdles for the chosen structure
Key Highlights
Board meeting held on July 23, 2026, to evaluate the restructuring of 100% subsidiary Nueclear Healthcare Limited
Pathology segment currently dominates the business mix, contributing 89% of total revenue
Restructuring options being explored include demerger, slump sale, or business transfer
NHL operates specialized PET-CT and CT imaging centers and medical cyclotron facilities
The evaluation process is in-principle; final terms and regulatory filings are pending
👀 What to Watch
Investors should watch for the specific mode of restructuring chosen; a slump sale would provide a cash infusion, while a demerger would likely result in shareholders receiving shares in a new entity.
34% PAT Growth in Q1 FY27; Revenue up 24% to ₹240 Cr with Record Franchisee Additions
Thyrocare reported a strong start to FY27 with consolidated revenue growing 24.3% YoY to ₹240.02 Cr, primarily driven by a 26% surge in pathology revenue. Profitability saw a significant boost as PAT rose 34.1% YoY to ₹51.33 Cr, supported by a 292 bps expansion in gross margins to 74.1%. The company achieved a record quarterly addition of approximately 900 active franchisees, bringing the total network to 11,730. While the core pathology business is scaling rapidly, the radiology segment saw a 4% revenue decline due to strategic exits from non-profitable centers.
Confidence: HIGH
What changedThyrocare has accelerated its network expansion with the highest quarterly franchisee additions in three years and achieved significant margin expansion through operational leverage.
Why it mattersThe strong volume growth (28% in tests) and margin improvement indicate that Thyrocare is successfully capturing market share from unorganized players while maintaining its 'affordable player' stance. The expansion into specialized testing (genomics, biomarkers) provides a path for higher value realization.
Consolidated Revenue (Q1 FY27): ₹240.02 CrPAT Growth (YoY): 34.1%Active Franchisees: 11,730EBITDA Margin: 32.2%Q1 Revenue vs TTM Revenue: ~29.4%Tests Conducted: 55.2 Mn
📅 Short termThe stock is likely to react positively to the strong double-digit growth in both revenue and PAT, alongside healthy margin expansion.
📈 Long termStructural growth remains intact as the company leverages its massive B2B network to cross-sell specialized tests and expands its footprint in underserved regions and international markets like Africa.
⚠ Risk flags
- Contraction in Radiology revenue (-4% YoY)
- Intense competition in the B2B diagnostic aggregator space
- Dependence on franchisee network for 64% of pathology revenue
Key Highlights
Consolidated Revenue increased 24.3% YoY to ₹240.02 Cr for Q1 FY27
PAT grew 34.1% YoY to ₹51.33 Cr with EBITDA margins expanding 226 bps to 32.2%
Record quarterly addition of ~900 active franchisees, reaching a total of 11,730
Pathology tests conducted rose 28% YoY to 55.2 million, serving 5.4 million patients
Gross margins improved by 292 bps YoY to 74.1% due to operational efficiencies
👀 What to Watch
Investors should monitor the sustainability of the 20%+ growth in pathology volumes and the success of the 'Routine to Remarkable' strategy in increasing revenue per patient through specialized tests. Watch for the stabilization of the radiology business and further expansion updates in the Tanzania international lab.
34% PAT Growth: Thyrocare Reports Robust Q1FY27 Results with ₹240 Cr Revenue
Thyrocare reported a strong start to FY27 with consolidated revenue growing 24% YoY to ₹240.02 crore, significantly outpacing the industry's mid-teen growth rate. Profitability improved faster than revenue, with EBITDA and PAT both surging 34% YoY to ₹77.27 crore and ₹51.33 crore respectively. The growth was volume-led, with test counts increasing 28% to 55.2 million. The company is also diversifying into high-margin specialty diagnostics like Genomics and Allergy testing to drive the next phase of growth.
Confidence: HIGH
What changedThyrocare has successfully accelerated its volume growth to 28% and transitioned into specialty diagnostics like Genomics (NIPT) and Allergy testing.
Why it mattersThe 34% PAT growth demonstrates high operating leverage, where the company's fixed-cost laboratory model allows profit to grow faster than revenue as volumes increase.
Q1 Revenue: ₹240.02 CrQ1 PAT: ₹51.33 CrRevenue vs TTM Revenue: 29.4%Test Volume Growth: 28% YoYEBITDA Margin: 32.2%
📅 Short termThe stock is likely to react positively to the strong double-digit growth in both top and bottom lines, which exceeds the company's historical TTM performance levels.
📈 Long termStructural expansion into specialty diagnostics and a growing franchise network (11,700+ centers) position the company to capture higher-value market segments beyond basic pathology.
⚠ Risk flags
- Intense pricing competition in the diagnostic industry
- Dependence on franchise partners for volume growth
- Execution risk in the new specialty genomics segment
Key Highlights
Consolidated revenue reached ₹240.02 Cr, a 24% increase over the previous year's quarter.
Net profit (PAT) grew by 34% YoY to ₹51.33 Cr, representing approximately 32.5% of the total TTM PAT.
Processed a record 55.2 million tests in Q1FY27, marking a 28% YoY volume growth.
Active franchise network expanded to approximately 11,700 centers, supporting a 27% YoY growth in franchise revenue.
Operational efficiency improved with complaints per million tests falling 24% YoY to 3.1.
👀 What to Watch
Monitor the revenue contribution and margin impact of the newly launched Specialty Diagnostics (Genomics and Allergy) in upcoming quarters. Watch for the sustainability of the 20%+ growth rate as the company expands into underserved regions.
Thyrocare Expands Business Scope to Include Manufacturing, Digital Platforms, and Non-Human Testing
Thyrocare Technologies received shareholder approval at its 26th AGM on June 30, 2026, to significantly broaden its Memorandum of Association (MOA). The amendments allow the company to venture into manufacturing and trading medical devices, developing digital healthcare platforms, and conducting non-human testing (animal, food, water, and soil). While pathology currently drives 89% of its Rs 815 Cr TTM revenue, these changes provide the legal framework for diversification into higher-margin medical equipment and broader diagnostic segments.
Confidence: HIGH
What changedThe company's Memorandum of Association was amended to include a wide array of new business activities including manufacturing, digital health, and non-human diagnostics.
Why it mattersThis provides the strategic flexibility to reduce dependence on human pathology (currently 89% of revenue) and enter new growth verticals like medical technology and environmental testing without further constitutional hurdles.
AGM Date: June 30, 2026Pathology Revenue Contribution: 89%TTM Revenue: Rs 815 CrActive Franchise Centers: 10,100+
📅 Short termNeutral impact on stock price as this is a procedural enabling resolution rather than an immediate financial event.
📈 Long termStructurally significant as it allows Thyrocare to evolve from a pure-play pathology lab into a diversified healthcare technology and manufacturing entity.
⚠ Risk flags
- Execution risk in entering non-core segments like manufacturing and animal testing
Key Highlights
Shareholders approved the 26th AGM resolutions on June 30, 2026, including major MOA amendments.
New Clause 1B enables the company to test non-human samples such as animal, plant, food, water, and soil.
The company is now authorized to manufacture, import, and distribute medical devices and point-of-care equipment.
Legal provisions added to develop and manage data-driven digital platforms and healthcare applications.
The amendment aligns the MOA with the Companies Act, 2013, replacing outdated 1956 Act references.
👀 What to Watch
Investors should monitor future capital expenditure announcements or M&A activity specifically targeting medical device manufacturing or environmental testing, as the legal groundwork for these diversifications is now complete.
Thyrocare Appoints Price Waterhouse as Statutory Auditors for 5-Year Term
Thyrocare Technologies has appointed M/s. Price Waterhouse Chartered Accountants LLP (PwC) as its statutory auditors for a five-year term, effective from June 30, 2026. This appointment follows the completion of the first term of the outgoing auditors, M S K A & Associates LLP. PwC, a member of a global network with over 125 assurance partners in India, will oversee the company's financial reporting until the 31st AGM in 2031. This transition to a top-tier audit firm is a standard governance practice for a company of this scale (Rs 4,110 Cr market cap).
Confidence: HIGH
What changedThe company has rotated its statutory auditors from M S K A & Associates to Price Waterhouse (PwC) following the completion of the former's term.
Why it mattersEngaging a 'Big Four' affiliated firm like PwC often enhances investor confidence in financial reporting and corporate governance, which is significant for a high-ROCE (36%) company.
Auditor Term: 5 yearsAGM Date: June 30, 2026PwC Assurance Partners: 125+TTM Revenue: Rs 815 CrMarket Cap: Rs 4110 Cr
📅 Short termNeutral. The change is administrative and unlikely to impact stock price or operations in the immediate weeks.
📈 Long termPositive for governance. A top-tier auditor provides better assurance for institutional investors as the company targets 18-22% growth and international expansion.
Key Highlights
Appointment of Price Waterhouse Chartered Accountants LLP for a 5-year term starting June 30, 2026.
Outgoing auditor M S K A & Associates LLP completed their first full term at the 26th AGM.
The new auditor, PwC, reported having more than 125 Assurance Partners as of December 31, 2025.
Appointment is valid until the conclusion of the 31st AGM to be held in 2031.
👀 What to Watch
Investors should monitor the upcoming quarterly results for any changes in accounting disclosures or notes that may arise from the transition to a new audit firm.
Rs 7.00 Final Dividend Approved; FY26 Revenue Grows 21% to Rs 829.04 Cr
Thyrocare's 26th AGM confirmed a final dividend of Rs 7.00 per share and highlighted a strong FY26 performance with consolidated revenue reaching Rs 829.04 crore (up 21% YoY). Net profit surged 79% to Rs 162.85 crore, supported by a 23% increase in test volumes to 210 million. Shareholders approved the appointment of Price Waterhouse as statutory auditors and the re-appointment of Rahul Franklin Guha as MD & CEO. The company is strategically expanding into specialized diagnostics, including genomics and allergy testing, while maintaining a network of 10,800+ active franchisees.
Confidence: HIGH
What changedShareholders formally ratified the FY26 financial results, the final dividend, the appointment of Price Waterhouse as new auditors, and leadership continuity.
Why it mattersThe results confirm robust operational scaling and a successful pivot toward higher-value specialized testing while maintaining high margins (OPM ~31.9%).
Final Dividend: Rs 7.00 per shareFY26 Revenue: Rs 829.04 CrFY26 PAT: Rs 162.85 CrTest Volume Growth: 23%Active Franchisees: 10,800+
📅 Short termPositive sentiment is expected as the strong growth figures and dividend are now officially ratified by shareholders.
📈 Long termThe structural shift toward specialized diagnostics (genomics/oncology) could re-rate the business if it successfully democratizes these high-margin tests.
⚠ Risk flags
- Competitive pricing pressure in the diagnostic industry
- Reliance on a large franchisee network for sample collection
Key Highlights
Consolidated revenue grew 21% YoY to Rs 829.04 crore in FY26
Net profit increased by 79% YoY to Rs 162.85 crore
Processed 210 million tests, representing a 23% volume growth
Final dividend of Rs 7.00 per share approved for the financial year
Network expanded to 10,800+ active franchisees across 5,400 pin codes
👀 What to Watch
Watch for the execution of the specialized diagnostics strategy, specifically the scaling of the Phadia allergy platform and NIPT genomic testing in upcoming quarterly results.
Thyrocare Recommends Final Dividend of ₹7.00 Per Share for FY 2025-26
Thyrocare Technologies has recommended a final dividend of ₹7.00 per equity share for the financial year ended March 31, 2026. This is in addition to the interim dividend of ₹7.00 already paid, bringing the total dividend for FY 2025-26 to ₹14.00 per share. The company has set June 23, 2026, as the record date and June 30, 2026, as the AGM date for shareholder approval. Detailed tax deduction at source (TDS) guidelines have been issued, requiring documentation submission by June 26, 2026.
Key Highlights
Recommended final dividend of ₹7.00 per equity share (70% of face value).
Total dividend for FY 2025-26 reaches ₹14.00 per share including interim payout.
Record date for dividend eligibility is fixed as Tuesday, June 23, 2026.
Standard TDS rate of 10% applies for resident shareholders with valid PAN.
Deadline for submitting tax-related declarations and documents is June 26, 2026.
👀 What to Watch
Investors should ensure their PAN and bank account details are updated with their DP and submit Form 15G/15H or other tax exemption documents by June 26 to minimize TDS.
Thyrocare to Hold 26th AGM on June 30; Sets June 23 as Record Date for Final Dividend
Thyrocare Technologies has scheduled its 26th Annual General Meeting (AGM) for June 30, 2026, to discuss the FY 2025-26 Annual Report. The company has fixed June 23, 2026, as the record date for determining shareholder eligibility for the final dividend. Shareholders can participate in remote e-voting between June 26 and June 29, 2026. Dividend payments are expected to be processed on or before July 29, 2026.
Key Highlights
26th Annual General Meeting scheduled for June 30, 2026, at 11:00 A.M. IST.
Record date for final dividend eligibility is Tuesday, June 23, 2026.
Dividend payment to be completed on or before Wednesday, July 29, 2026.
E-voting period starts June 26, 2026, and ends June 29, 2026.
Annual Report for FY 2025-26 and AGM Notice have been made available via digital links.
👀 What to Watch
Investors seeking the final dividend should ensure they hold shares by the June 23 record date. Shareholders are also encouraged to review the Annual Report to evaluate the company's financial health and strategic direction.
Thyrocare Sets June 23 as Record Date for ₹7.00 Final Dividend for FY26
Thyrocare Technologies has fixed June 23, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹7.00 per share for the financial year ended March 31, 2026. The dividend is subject to approval at the 26th Annual General Meeting (AGM) scheduled for June 30, 2026. If approved, the payout will be completed on or before July 29, 2026. This dividend represents a 70% payout on the face value of ₹10 per share.
Key Highlights
Final dividend of ₹7.00 per equity share recommended for FY 2025-26.
Record date for determining eligibility is Tuesday, June 23, 2026.
26th Annual General Meeting (AGM) scheduled for June 30, 2026.
Dividend payment to be completed on or before July 29, 2026.
👀 What to Watch
Investors interested in the dividend must ensure they hold the shares in their demat account before the ex-dividend date. Long-term investors should monitor the company's yield and payout consistency as part of their portfolio strategy.
Thyrocare FY26 Revenue Grows 21% to ₹829 Cr; PAT Surges 79% to ₹163 Cr; AGM on June 30
Thyrocare Technologies delivered a robust performance in FY 2025-26, with revenue from operations increasing 21% YoY to ₹829.04 crore. Profit After Tax (PAT) witnessed a massive 79% jump to ₹162.85 crore, driven by operational efficiencies and network expansion. The company expanded its lab footprint to 41 locations and its test menu to over 1,275 tests. Additionally, the company declared a dividend of ₹9.33 per share (restated for the 2:1 bonus issue) and successfully integrated Think Health for home ECG services.
Key Highlights
Revenue from operations grew 21% YoY to ₹829.04 crore in FY26 compared to ₹687.35 crore in FY25.
Profit After Tax (PAT) surged by 79% to ₹162.85 crore, up from ₹90.75 crore in the previous year.
Expanded laboratory network to 41 labs (including 7 new labs) and increased test menu to 1,275+ tests.
EBITDA increased by 34% YoY to ₹255.88 crore with a significant improvement in margins.
Proposed dividend of ₹9.33 per share, adjusted for the 2:1 bonus issue completed during the fiscal year.
👀 What to Watch
Investors should note the strong recovery in profitability and aggressive network expansion. The company's shift toward specialized diagnostics and home-based services like ECG makes it a competitive player in the diagnostic sector; hold for long-term growth.
Thyrocare Promoter Docon Technologies Reports 60.93% Total Shareholding Pledged in FY26 Disclosure
Docon Technologies, the promoter of Thyrocare, has filed its annual disclosure under SEBI Takeover Regulations for the financial year ended March 31, 2026. The filing confirms that the promoter's entire 60.93% stake in the company remains encumbered. Notable activity during the year included a pledge modification following a 2:1 bonus issue in December 2025, which brought the total pledged shares to 9,69,69,696. This disclosure is a routine compliance measure to ensure transparency regarding promoter share encumbrances.
Key Highlights
Promoter Docon Technologies and API Holdings confirm 60.93% of total share capital is pledged.
A 2:1 bonus issue in December 2025 led to the encumbrance of 6.46 crore additional shares.
The total number of shares under pledge stands at 9,69,69,696 as of March 31, 2026.
The filing confirms no new undisclosed encumbrances were created during the 2025-26 financial year.
👀 What to Watch
Monitor the high promoter pledge (100% of their stake) as a risk factor for potential volatility. No immediate action is needed as this is a routine regulatory confirmation of existing encumbrances.
Thyrocare Q4 FY26: Revenue Grows 20% YoY; Specialized Jaanch Segment Surges 66%
Thyrocare reported a robust 21% YoY consolidated revenue growth for FY26, supported by a 23% increase in test volumes to 210 million. The specialized 'Jaanch' segment showed exceptional growth of 66% in Q4, while the flagship 'Aarogyam' brand grew 20%. Despite a slight dip in the partnership segment's Q4 growth to 23% due to a high base effect of INR 4 crore from the previous year, the company expanded its network to 10,800 franchisees and 41 labs globally. Strategic forays into genomics and the African market (Tanzania) signal a shift towards high-margin specialty diagnostics and geographic diversification.
Key Highlights
Consolidated revenue grew 21% YoY in FY26, with Q4 revenue increasing by 20% YoY.
Processed 210 million tests in FY26 (up 23% YoY) and served 19.2 million patients (up 15% YoY).
The specialized 'Jaanch' portfolio surged 66% YoY in Q4, reflecting a shift toward disease-specific testing.
Active franchisee network reached a record 10,800, while the lab network expanded to 41 locations including Tanzania.
Maintained Six Sigma quality levels with complaints reduced to 3.06 per million tests and a turnaround time of 3.43 hours.
👀 What to Watch
Investors should monitor the scaling of the high-margin genomics and specialty segments, which are expected to drive future profitability. The company's expansion into Africa and its dominant B2B partnership growth make it a strong contender in the organized diagnostic space.
Thyrocare Declares ₹7 Final Dividend and ₹5.5 Cr Investment in Subsidiary
Thyrocare's board has recommended a final dividend of ₹7.00 per share, bringing the total dividend for FY26 to ₹9.33 per share post-bonus adjustment. The company is investing up to ₹5.50 crore in its wholly-owned subsidiary, Think Health Diagnostics, to bolster its diagnostic capabilities. Leadership remains stable with the re-appointment of Rahul Franklin Guha as MD & CEO for a five-year term. Furthermore, the company is broadening its business scope via MOA amendments to include digital healthcare platforms and allied services.
Key Highlights
Recommended a final dividend of ₹7.00 per equity share for FY 2025-26.
Total FY26 dividend stands at ₹9.33 per share post-bonus adjustment.
Approved equity infusion of up to ₹5.50 crore in Think Health Diagnostics Private Limited.
Re-appointed Rahul Franklin Guha as MD & CEO for a 5-year term starting May 2027.
Proposed MOA alteration to expand business into digital platforms and broader healthcare services.
👀 What to Watch
Investors should take note of the consistent dividend payout and leadership continuity as positive indicators of corporate health. The strategic expansion into digital diagnostic platforms and allied services suggests a long-term growth roadmap beyond traditional pathology.
